HDAC9 and atherosclerosis: Trichostatin A, a reversible and specific HDAC inhibitor, blocks the upregulation of markers associated with endothelial dysfunction and reactive oxygen species (ROS) in uremic conditions, making it a potential treatment for atherosclerosis and CAD [118].